Phase 3 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older at the time of signing the consent form
- You have been diagnosed with palmoplantar pustulosis (a skin condition causing painful blisters/pustules on the palms and soles) for at least 24 weeks before your first screening appointment
- Your condition is rated as moderately severe or above on two specific skin scoring scales, measured at both your screening and baseline appointments (confirm with trial site)
- You have more than 5 active pustules (fluid-filled bumps) on your palms and/or soles, with a pustule severity score of 2 or higher, at both your screening and baseline appointments
- Your doctor considers you a suitable candidate for treatment that works throughout the whole body (such as tablets or injections) or light-based therapy
Who may not be able to join:
- Your skin condition improved significantly between your screening appointment and your baseline appointment
- You have been diagnosed with certain other skin conditions, including other forms of psoriasis, atopic dermatitis, or certain types of eczema (confirm with trial site for the full list)
- Your pustules or skin condition were caused or made worse by certain medications, such as beta blockers, lithium, or some heart or immune system medicines
- You have other skin lesions (marks or sores) that might make it difficult for doctors to properly assess your condition
- You are taking, or have recently taken, certain medications without completing a required waiting or stopping period before the baseline appointment (confirm with trial site)
- You have ever taken a specific type of medication called an IL-17A/IL-17F inhibitor (including a drug called bimekizumab), or you have previously taken part in a clinical study involving bimekizumab
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: UCB Cares, 001 844 599 22733 (UCB)
Phone: +18445992273
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Palmoplantar pustulosis-Investigator Global Assessment 0/1 (PPP-IGA 0/1) response at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.